Orano Med
Pascal Mirocha has over 30 years of experience in finance and management. Pascal most recently served as the Chief Financial Officer and Director at Orano Med. Prior to that, they held finance director roles at AntemetA, HEMARINA, and CARE FUSION FRANCE & BELGIUM. Pascal also worked as a Finance Manager at ACTIV CONSULTING, where they managed various international finance and management projects. Pascal has extensive experience in implementing production units and sales offices, improving financial performance, and establishing financial guidelines and controls. Pascal has a proven track record of driving profitability and successfully leading finance functions.
Pascal Mirocha's education history begins with earning a Masters Degree in Economics and Administration from UNIVERISTY PARIS 8, which they completed in 1988. Before that, they pursued a Degree in Finance Accounting from PARISXIII from 1984 to 1986. Additionally, in 1992, they attended the Franco-British Chamber of Commerce to study English for Business. The duration of their program in the Franco-British Chamber of Commerce is not provided.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.